News
TechBio
DCVC perspectives on TechBio, the data-centric, AI-native counterweight to traditional biotech.
Inside: portfolio updates and analysis on the companies turning biology into a programmable platform for new medicines.
Showing 1–11 of 11
Deep Tech Opportunities Report
Deep Tech Opportunity: TechBio companies are using data to rethink how we develop new medical treatments
News
Proxima raises $80M in seed financing, led by DCVC, to reprogram protein-protein interactions
News
Noetik’s partnership with GSK puts dollar signs on the AI licensing business model in TechBio
Company Profile
Why Kanvas built its own production line for microbiome therapeutics
News
Relation unveils atopic diseases agreement with Novartis—$55 million up front and up to $1.7 billion in milestone-based payments; DCVC, NVIDIA NVentures, and Magnetic Ventures co-lead $26M fundraise
Snapshot
Kanvas Bio speeds the search for microbiome therapies through industrial-scale imaging of gut and host cells
Deep Tech Opportunities Report
DCVC DTOR 2024: TechBio is emerging as the data-centric, AI-native counterweight to biotech
News
Relation Therapeutics partners with GSK in history-making collaboration to create new treatments for fibrosis and osteoarthritis
News
DCVC leads $35 million financing to help UK TechBio leader Relation Therapeutics to seek new treatments for complex diseases
Thoughts